Surface Oncology Inc (NASDAQ:SURF) Short Interest Down 8.5% in July
Surface Oncology Inc (NASDAQ:SURF) saw a significant drop in short interest in July. As of July 31st, there was short interest totalling 138,100 shares, a drop of 8.5% from the June 30th total of 150,900 shares. Based on an average daily trading volume, of 67,300 shares, the short-interest ratio is presently 2.1 days. Approximately 1.3% of the shares of the stock are short sold.
A number of brokerages recently issued reports on SURF. ValuEngine upgraded Surface Oncology from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen reiterated a “buy” rating on shares of Surface Oncology in a research report on Thursday, May 9th. Finally, Zacks Investment Research downgraded Surface Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday.
NASDAQ SURF traded up $0.03 during trading hours on Thursday, reaching $2.05. 22,103 shares of the stock traded hands, compared to its average volume of 64,461. The stock has a 50 day simple moving average of $2.46 and a two-hundred day simple moving average of $3.87. Surface Oncology has a 1 year low of $1.95 and a 1 year high of $12.65. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.77 and a quick ratio of 8.77. The company has a market cap of $57.11 million, a price-to-earnings ratio of -6.21 and a beta of 2.38.
Surface Oncology Company Profile
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.
See Also: Discount Rate
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.